Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.49 |
| ▸ | ILK | Q13418 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673100 | 0.91 | EGFR (0.46) | EGFRILKKDRGAKKDM1A | |
| SCHEMBL24938199 | 0.79 | EGFR (0.52) | EGFRILKKDRGAKKDM1A | |
| SCHEMBL22594996 | 0.72 | EGFR (0.74) | EGFRILKKDRGAKAURKB | |
| SCHEMBL24353219 | 0.71 | EGFR (0.55) | EGFRILKKDRGAKKDM1A | |
| SCHEMBL20673045 | 0.68 | EGFR (0.82) | EGFRILKKDRGAKAURKB | |
| SCHEMBL19146731 | 0.68 | EGFR (0.82) | EGFRILKKDRGAKAURKB | |
| SCHEMBL28407634 | 0.66 | ENPP1 (0.63) | EGFRKDRGAKKDM1A | |
| SCHEMBL28412498 | 0.66 | ENPP1 (0.63) | EGFRKDRGAKKDM1A | |
| SCHEMBL1507409 | 0.66 | EGFR (1.00) | EGFRILKKDRGAKAURKB | |
| SCHEMBL29354959 | 0.66 | EGFR (1.00) | EGFRILKKDRGAKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710968-B2 | Radiolabeled erlotinib analogs and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2020-07-14 | — | — | US | disclosed |
| US-20190023664-A1 | RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710968-B2 | Radiolabeled erlotinib analogs and uses thereof | EGFR, KRAS, ERBB4 | EGFR 1/4885ILK 3262/4885KDR 64/4885 |
| US-20190023664-A1 | RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF | EGFR, KRAS, ERBB4 | EGFR 1/4885ILK 3262/4885KDR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.